Nuvelution Puts Business Model Into Action With Teva/Austedo Deal
Focused on drug development risk-sharing partnerships, Nuvelution signs its first partnership, with Teva, to conduct Phase III development of recently approved Austedo for pediatric Tourette syndrome.
